| scholarly article | Q13442814 |
| P50 | author | Rami Burstein | Q78769205 |
| P2093 | author name string | Dan Levy | |
| Moshe Jakubowski | |||
| Beth Collins | |||
| Itay Goor-Aryeh | |||
| Zahid Bajwa | |||
| P2860 | cites work | A functional analysis of EP4 receptor-expressing neurons in mediating the action of prostaglandin E2 within specific nuclei of the brain in response to circulating interleukin-1beta | Q28580102 |
| The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine | Q33910986 | ||
| Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity | Q33939152 | ||
| Glial activation: a driving force for pathological pain | Q33953790 | ||
| Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. | Q34287678 | ||
| Spinal cord glia: new players in pain | Q34341903 | ||
| Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists | Q37357042 | ||
| Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial | Q39235777 | ||
| Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients | Q39476698 | ||
| Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients | Q39490000 | ||
| A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine | Q39500476 | ||
| Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches | Q39507391 | ||
| Common problems in pediatric ambulatory surgery: upper respiratory infection, heart murmur, or sickle-cell disease | Q40806715 | ||
| Treatment patterns of isolated benign headache in US emergency departments | Q43898377 | ||
| A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine | Q44481364 | ||
| Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. | Q44713176 | ||
| A novel interaction between dynorphin(1-13) and an N-methyl-D-aspartate site | Q45816731 | ||
| Ultrastructural analysis of dynorphin B-immunoreactive cells and terminals in the superficial dorsal horn of the deafferented spinal cord of the rat. | Q46226399 | ||
| Dynorphin A increases substance P release from trigeminal primary afferent C-fibers | Q48271922 | ||
| Mechanical response properties of A and C primary afferent neurons innervating the rat intracranial dura | Q48432736 | ||
| Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study | Q48960051 | ||
| Inflammatory mediators potentiate pain induced by experimental tissue acidosis. | Q50998076 | ||
| An association between migraine and cutaneous allodynia. | Q51402389 | ||
| P433 | issue | 7 | |
| P921 | main subject | migraine | Q133823 |
| central sensitization | Q21087540 | ||
| P304 | page(s) | 850-861 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Headache | Q5689497 |
| P1476 | title | Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors | |
| P478 | volume | 45 |
| Q51113636 | 2007 Scottsdale Headache Symposium. |
| Q33624316 | A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats |
| Q21091071 | Acetate causes alcohol hangover headache in rats |
| Q38028610 | Acute treatment of migraines |
| Q38730883 | Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study |
| Q46191353 | Allodynia as a complication of migraine: background and management |
| Q37409505 | Allodynia in migraine: frequent random association or unavoidable consequence? |
| Q39316816 | Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia |
| Q46051400 | Almotriptan efficacy in migraine with allodynia: a critique of Schoenen et al. |
| Q39175620 | An Algorithm for Opioid and Barbiturate Reduction in the Acute Management of Headache in the Emergency Department |
| Q37699421 | Animal models of headache: from bedside to bench and back to bedside |
| Q37798757 | Are the current IHS guidelines for migraine drug trials being followed? |
| Q38227997 | COX inhibitors for the treatment of migraine |
| Q36641567 | Central sensitization theory of migraine: clinical implications |
| Q39433702 | Cervico-cephalalgiaphobia: a subtype of phobia in patients with cervicogenic headache and neck pain? A pilot study. |
| Q41282006 | Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats |
| Q37189727 | Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: limited efficacy, risks, and proposed guidelines |
| Q34096610 | Current approaches to the diagnosis and management of paediatric migraine |
| Q45908236 | Current management of migraine in US emergency departments: an analysis of the National Hospital Ambulatory Medical Care Survey. |
| Q47653067 | Current management: migraine headache |
| Q37263436 | Cutaneous allodynia and migraine: another view |
| Q24651176 | Diagnosis and management of the primary headache disorders in the emergency department setting |
| Q33633047 | Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience |
| Q42854066 | Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT) |
| Q34581061 | Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel gro |
| Q36641480 | Eletriptan: a review and new perspectives |
| Q38217747 | Evaluation and treatment of migraine in the emergency department: a review |
| Q37271327 | Excitatory neurotransmitters in brain regions in interictal migraine patients |
| Q36345242 | Headache: a good year for research |
| Q37855782 | Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache |
| Q39345858 | Inhibitory effect of high-frequency greater occipital nerve electrical stimulation on trigeminovascular nociceptive processing in rats |
| Q37263431 | Insights from experimental studies into allodynia and its treatment |
| Q38129436 | Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine |
| Q34308609 | Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial |
| Q46550880 | Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats |
| Q89863298 | Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache |
| Q33978721 | Ionic mechanisms underlying inflammatory mediator-induced sensitization of dural afferents |
| Q30466790 | Italian guidelines for primary headaches: 2012 revised version |
| Q36947150 | Less is not more: underutilization of headache medications in a university hospital emergency department |
| Q37417107 | Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. |
| Q37744888 | Management of headache in the elderly |
| Q42917914 | Managing migraine associated with sensitization |
| Q38083018 | Mechanism of action of indomethacin in indomethacin-responsive headaches |
| Q34362586 | Medication overuse headache: history, features, prevention and management strategies |
| Q37409407 | Medullary pain facilitating neurons mediate allodynia in headache-related pain |
| Q35338284 | Migraine attacks the Basal Ganglia |
| Q47793574 | Migraine: possible role of shear-induced platelet aggregation with serotonin release. |
| Q33346870 | Migraine: where and how does the pain originate? |
| Q34407137 | Modelling headache and migraine and its pharmacological manipulation |
| Q42882632 | Neurophysiological markers of central sensitisation in the trigeminal pathway and their modulation by the cyclo-oxygenase inhibitor ketorolac |
| Q60930835 | Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity |
| Q34180539 | One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. |
| Q33640173 | Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity |
| Q38152801 | Opioids in headache |
| Q38006003 | Opioids should not be used in migraine |
| Q52656846 | PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. |
| Q46502526 | Pathophysiology of migraine and clinical implications |
| Q38438227 | Patient characteristics associated with frequent calls to a headache specialty clinic |
| Q37973436 | Pharmacological synergy: the next frontier on therapeutic advancement for migraine |
| Q46136517 | Prostaglandin E2(PGE2) induces headache in healthy subjects |
| Q45926654 | Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. |
| Q47240430 | Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine |
| Q37189724 | Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies? |
| Q41963362 | Remarks on an educational training course on headache |
| Q34243951 | Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium |
| Q37992176 | Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications |
| Q24648979 | Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion |
| Q37181373 | Sensitization of meningeal nociceptors: inhibition by naproxen |
| Q30465785 | Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology |
| Q36951346 | Sensitization, glutamate, and the link between migraine and fibromyalgia |
| Q35888199 | Sex-, Stress-, and Sympathetic Post-Ganglionic Neuron-Dependent Changes in the Expression of Pro- and Anti-Inflammatory Mediators in Rat Dural Immune Cells |
| Q40224193 | Spinal trigeminal neurons demonstrate an increase in responses to dural electrical stimulation in the orofacial formalin test |
| Q42614801 | Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention |
| Q35226089 | Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons |
| Q82704934 | Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates |
| Q47327177 | Terminating Migraine-Associated Allodynia Using Oral Suspension Diclofenac: A Prospective Non-Randomized Drug Trial |
| Q37252452 | The blood-brain barrier in migraine treatment |
| Q34611911 | The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model |
| Q57023896 | The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers |
| Q43289884 | The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission |
| Q36311006 | The long-term prognosis of tension-type headache |
| Q37900861 | The paradoxical effects of analgesics and the development of chronic migraine |
| Q37986274 | The science of migraine |
| Q38392414 | Therapeutic prospects for migraine: can paradise be regained? |
| Q34419654 | Therapeutic use of botulinum toxin in migraine: mechanisms of action |
| Q38879331 | Treatment of acute migraine in the emergency department |
| Q44339094 | Treatment-refractory migraine: the case for opioid therapy |
| Q42871975 | Triptan Therapy in Migraine |
| Q43107488 | Triptan-induced latent sensitization: a possible basis for medication overuse headache |
| Q38680371 | Update of Inpatient Treatment for Refractory Chronic Daily Headache |
| Q33747971 | Update on Hemicrania Continua |
| Q58714299 | Volume Gain of Brainstem on Medication-Overuse Headache Using Voxel-Based Morphometry |
| Q46633266 | Le traitement de la migraine aiguë à l’urgence |
Search more.